Key result
Dabigatran 150 mg was associated with lower rates of stroke and systemic embolism than warfarin, whereas dabigatran 110 mg had similar efficacy but lower rates of major hemorrhage.
Why the study?
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
RCT
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
Dabigatran provides a dose-dependent alternative to warfarin for stroke prevention in atrial fibrillation, with the 150 mg dose offering superior efficacy and the 110 mg dose offering superior safety regarding major hemorrhage.
May support dabigatran as alternative to warfarin in AF; leaves open optimal dosing and real-world validation.
ConclusionsIn patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.(ClinicalTrials.govnumber, NCT00262600.)
No takes yet. Share an insight, caveat, or question.
Houston et al. (2009) conducted an RCT in Atrial fibrillation. Dabigatran vs. Warfarin was evaluated on Stroke and systemic embolism. Dabigatran 150 mg was associated with lower rates of stroke and systemic embolism than warfarin, whereas dabigatran 110 mg had similar efficacy but lower rates of major hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: